

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/763,616 05/16/2001		Hans-Ulrich Bernard	REF/BERNARD	6676	
75	90 08/12/2002	•			
Bacon & Thomas 625 Slaters Lane 4th Floor Alexandria, VA 22314-1176			EXAMINER		
			KWON, BRIAN YONG S		
			ART UNIT	PAPER NUMBER	
			1614		
			DATE MAILED: 08/12/2002	8	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application	No.	Applicant(s)				
•		09/763,616		BERNARD ET AL.				
	Office Action Summary	Examiner	 	Art Unit				
		Brian S Kwor	· 1	1614				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address								
Period for Reply A SHORTENED STATISTORY DEDICE FOR BEDLY IS SET TO EXPIRE 4 MONTH(S) EDOM								
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status								
1) 🖂	Responsive to communication(s) filed on 02 M	March 2001						
2a)		is action is no	n-final.					
3)	·—							
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims								
4)⊠	4) Claim(s) 1-36,39 and 40 is/are pending in the application.							
	4a) Of the above claim(s) is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.								
6) Claim(s) is/are rejected.								
7)	7) Claim(s) is/are objected to.							
8) Claim(s) 1-36,39 and 40 are subject to restriction and/or election requirement.								
· · ·	on Papers	_						
9) The specification is objected to by the Examiner.								
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.								
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). 11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.								
If approved, corrected drawings are required in reply to this Office action.								
12) The oath or declaration is objected to by the Examiner.								
Priority under 35 U.S.C. §§ 119 and 120								
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).								
a) ☐ All b) ☐ Some * c) ☐ None of:								
/-	1. Certified copies of the priority documents have been received.							
	2. Certified copies of the priority documents have been received in Application No							
	3. Copies of the certified copies of the priority documents have been received in this National Stage							
application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.								
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).								
 a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. 								
Attachment(s)								
2) Notice	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s) <u>5</u>	5)		mmary (PTO-413) Paper No(s) ormal Patent Application (PTO-152)				

Application/Control Number: 09/763,616

Art Unit: 1614

DETAILED ACTION

By Amendment filed March 02, 2001, claims 37 and 38 have been cancelled and claims 7, 20 and 34-35 have been amended. Claims 1-36 and 39-40 are currently pending.

Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group (I), claim(s) 1-12, drawn to a method of identifying compounds useful in the treatment of a disease condition caused or exacerbated by an MPV.

Group (II), claim(s) 13-35 and 40, drawn to a method of treating or preventing a disease condition caused or exacerbated by an MPV.

Group (III), claim(s) 36 and 39, drawn to a composition comprising a compound of general formula I or II.

The inventions listed as Groups I-III do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT rule 13.2, they lack the same or corresponding special technical features for the following reasons: The technical feature linking groups I-III appears to that they all relate to a composition comprising a compound of general formula (I) or (II).

Application/Control Number: 09/763,616

Art Unit: 1614

However, the claimed compositions are known in the art (JP4-208223; Synlett, August 1990, pages 473-476; JP 7-233057 A; JP 1207376 A; JP 3-178148 A; JP 2-304346 A; JP 3-063258; EP 562750; WO 96/09406; Chemical Abstracts 102:8009; Journal of Medicinal Chemistry, volumn39 No: 19, 1996, pages 3606-3616; etc...) Therefore, the technical feature linking the inventions of groups I-III does not constitute a special technical feature as defined by PCT Rule 13.2, as it does not define a contribution over the prior art. Accordingly, Groups I-III are not linked by the same or a corresponding special technical feature as to form a single general inventive concept

2. This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

Applicant is required, in reply to this action, to elect a single disclosed species from the general formula I or II to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added.

- 3. Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.
- 4. With the election of the specific species, a generic concept will be identified by the examiner as the inventive group for examination.

Page 4

5. Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Brian Kwon whose telephone number is (703) 308-5377. The

examiner can normally be reached Tuesday through Friday from 9:00 am to 7:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Marianne Seidel, can be reached on (703) 308-4725. The fax number for this Group

is (703) 308-4556.

Any inquiry of a general nature of relating to the status of this application or proceeding

should be directed to the Group receptionist whose telephone number is (703) 308-1235.

Brian Kwon

ZOHREH FAY PRIMARY EXAMINER GROUP 1600